IRVINE, Calif.–(BUSINESS WIRE)– #clinicaltrials–Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conju
http://www.businesswire.com/images/Powered-by-Business-Wire.gifGo to Source
https://feed.businesswire.com/rss/home/?rss=G1QFDERJXkJeEVlZWA==&_gl=1*1m4yt6c*_gcl_au*ODY2ODgwODguMTczNjM1MjA5OA..*_ga*MTQ4NTQ4MjYyMi4xNzM2MzUyMDk4*_ga_ZQWF70T3FK*MTczNjM1MjA5OC4xLjEuMTczNjM1MjIwOS42MC4wLjA.